首頁 > 市場調查報告書 > 製藥

癌症

胃癌藥物市場規模、佔有率和成長分析（按治療方法、疾病、藥物類別和地區分類）—產業預測（2026-2033 年）

市場調查報告書

商品編碼

1897224

胃癌藥物市場規模、佔有率和成長分析（按治療方法、疾病、藥物類別和地區分類）—產業預測（2026-2033 年）

Gastric Cancer Drugs Market Size, Share, and Growth Analysis, By Treatment Type, By Disease Indication (Gastric Adenocarcinoma, Gastrointestinal Stromal Tumor ), By Drug Class, By Region -Industry Forecast 2026-2033

出版日期: 2025年12月19日 | 出版商:

SkyQuest | 英文 195 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球胃癌藥物市場規模預計在 2024 年達到 60.2 億美元，從 2025 年的 67.1 億美元成長到 2033 年的 160.4 億美元，在預測期（2026-2033 年）內複合年成長率為 11.5%。

由於胃癌發病率不斷上升和藥物研發取得突破性進展，全球胃癌藥物市場正經歷顯著成長。肥胖率上升、吸菸率上升、飲食習慣改變以及幽門螺旋桿菌病菌感染的廣泛流行等因素，都促使人們對有效治療方法的需求日益成長。包括標靶治療和免疫療法在內的藥物創新正在革新診斷技術並改善患者預後。不斷上漲的醫療成本、強勁的研發投入以及有利的法規環境進一步推動了市場擴張。然而，挑戰依然存在，例如高昂的藥物研發成本、嚴格的監管以及低收入社區藥物取得的不公平性。儘管存在這些障礙，但專注於聯合治療、生物相似藥和個人化醫療的豐富研發管線有望塑造胃癌藥物市場的未來格局。

推動全球胃癌藥物市場發展的因素

標靶治療和免疫療法的日益普及和核准，正顯著推動全球胃癌治療市場的成長。與傳統化療相比，HER2抑制劑和PD-1/PD-L1查核點抑制劑等創新療法具有更高的療效和安全性。這些先進治療方法旨在針對特定的基因突變或免疫查核點，為治療性介入創造了新的契機，並顯著改善了相當一部分胃癌患者的治療效果。隨著大型臨床試驗不斷證實這些新型治療方法的優越性，監管機構和醫療專業人員的快速採納正推動市場顯著擴張。

限制全球胃癌藥物市場的因素

新型標靶治療和免疫療法的高昂價格是全球胃癌治療市場成長的一大障礙。這些先進療法通常價格昂貴，反映了其龐大的研發成本、複雜的生產流程以及伴隨診斷的必要性。因此，能否獲得這些療法主要取決於經濟能力，這對中低收入國家的患者構成了重大障礙。此外，即使在高所得國家，醫保報銷的挑戰和預算限制也會阻礙這些療法的廣泛應用。這些與成本相關的障礙阻礙了患者獲得治療，並減緩了整個市場的發展。

全球胃癌藥物市場趨勢

全球胃癌治療市場正呈現出顯著的趨勢，即採用創新治療方法和精準醫療。隨著生物製藥和標靶治療的進步，醫療服務提供者正致力於為癌症患者量身定做個人化治療方案，以滿足其獨特的基因特徵。這項轉變的驅動力在於研發活動的增加以及對早期診斷和介入策略日益重視。人工智慧等先進技術的融合正在提升藥物研發流程和病患監測，從而改善治療效果。隨著人們對有效胃癌療法的認知和需求不斷提高，預計該市場將迎來強勁成長。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Imugene Limited（Australia）
Otsuka Pharmaceuticals Co., Ltd（Japan）
F. Hoffmann-La Roche Ltd（Switzerland）
Merck KGaA（Germany）
Bristol-Myers Squibb Company（US）
Novartis AG（Switzerland）
Lilly（US）
Sanofi（France）
Amgen Inc.（US）
Bayer AG（Germany）
Gilead Sciences, Inc.（US）
AstraZeneca（UK）
Ipsen Pharma（France）
Takeda Pharmaceutical Company Limited（Japan）
Biosplice Therapeutics, Inc.（US）
Arbutus Biopharma（Canada）
ASLAN Pharmaceuticals（Singapore）

結論與建議

簡介目錄

Product Code: SQMIG35I2393

Global Gastric Cancer Drugs Market size was valued at USD 6.02 Billion in 2024 and is poised to grow from USD 6.71 Billion in 2025 to USD 16.04 Billion by 2033, growing at a CAGR of 11.5% during the forecast period (2026-2033).

The global market for gastric cancer drugs is experiencing significant growth driven by increasing incidence rates and groundbreaking advancements in drug development. Factors such as rising obesity, smoking rates, and dietary habits, coupled with the widespread prevalence of Helicobacter pylori infections, contribute to a higher demand for effective treatment options. Innovations in pharmaceuticals, including targeted therapies and immunotherapies, are transforming diagnostics and improving patient outcomes. Enhanced healthcare spending, robust R&D investments, and supportive regulatory environments further stimulate market expansion. However, challenges remain, including high drug development costs, stringent regulations, and access disparities in low-income regions. Despite these hurdles, a rich pipeline focusing on combination therapies, biosimilars, and personalized medicine is poised to shape the future landscape of the gastric cancer drug market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gastric Cancer Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Gastric Cancer Drugs Market Segments Analysis

Global Gastric Cancer Drugs Market is segmented by Type, Treatment Type, Drug Type, Route of Administration, End-Users and region. Based on Type, the market is segmented into Adenocarcinoma, Lymphoma, Gastrointestinal Stromal Tumor, Carcinoid Tumor and Others. Based on Treatment Type, the market is segmented into Chemotherapy, Targeted Therapy, Immunotherapy, Surgery, Radiation Therapy, Medication and Others. Based on Drug Type, the market is segmented into Doxorubicin Hydrochloride, Sunitinib, Mitomycin, Imatinib, Fluorouracil, Trastuzumab and Others. Based on Route of Administration, the market is segmented into Oral and Injectable. Based on End-Users, the market is segmented into Hospitals, Homecare, Specialty Clinics and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Gastric Cancer Drugs Market

The rising availability and approval of targeted therapies and immunotherapies are significantly propelling growth in the global gastric cancer drug market. Innovations such as HER2 inhibitors and PD-1/PD-L1 checkpoint inhibitors offer enhanced efficacy and safety when contrasted with traditional chemotherapy methods. These advanced treatments are designed to specifically address actionable genetic mutations and immune checkpoints, thus creating new opportunities for therapeutic interventions and enhancing patient outcomes for a notable segment of the gastric cancer population. As pivotal clinical trials increasingly demonstrate the advantages of these novel treatments, their swift adoption by regulatory bodies and healthcare professionals is driving substantial market expansion.

Restraints in the Global Gastric Cancer Drugs Market

The elevated prices associated with novel targeted therapies and immunotherapies present a notable hurdle for growth in the Global Gastric Cancer Drugs market. These advanced treatments often come with premium price tags, reflecting substantial research and development expenditures, intricate manufacturing processes, and the necessity for companion diagnostics. As a result, access to these therapies is largely dependent on financial capability, posing a significant barrier to patients in low- and middle-income countries. Furthermore, even in high-income economies, reimbursement challenges and budgetary limitations can hinder broader adoption. Consequently, these cost-related barriers impede patient access and slow the overall advancement of the market.

Market Trends of the Global Gastric Cancer Drugs Market

The Global Gastric Cancer Drugs market is witnessing a significant trend towards the adoption of innovative treatment modalities and precision medicine. With advancements in biologics and targeted therapies, healthcare providers are focusing on personalized treatment plans tailored to the unique genetic profiles of cancer patients. This shift is being driven by increased research and development activities, along with a growing emphasis on early diagnosis and intervention strategies. The integration of cutting-edge technologies, such as artificial intelligence, is enhancing drug discovery processes and patient monitoring, resulting in improved outcomes. As awareness and demand for effective gastric cancer treatments rise, the market is poised for robust growth.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Analysis
Technology Analysis
Case Studies
Customer Buying Behavior Analysis

Global Gastric Cancer Drugs Market Size by Type & CAGR (2026-2033)

Market Overview
Adenocarcinoma
Lymphoma
Gastrointestinal Stromal Tumor
Carcinoid Tumor
Others

Global Gastric Cancer Drugs Market Size by Treatment Type & CAGR (2026-2033)

Market Overview
Chemotherapy
Targeted Therapy
Immunotherapy
Surgery
Radiation Therapy
Medication
Others

Global Gastric Cancer Drugs Market Size by Drug Type & CAGR (2026-2033)

Market Overview
Doxorubicin Hydrochloride
Sunitinib
Mitomycin
Imatinib
Fluorouracil
Trastuzumab
Others

Global Gastric Cancer Drugs Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Oral
Injectable

Global Gastric Cancer Drugs Market Size by End-Users & CAGR (2026-2033)

Market Overview
Hospitals
Homecare
Specialty Clinics
Others

Global Gastric Cancer Drugs Market Size & CAGR (2026-2033)

North America (Type, Treatment Type, Drug Type, Route of Administration, End-Users)
- US
- Canada
Europe (Type, Treatment Type, Drug Type, Route of Administration, End-Users)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Type, Treatment Type, Drug Type, Route of Administration, End-Users)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Type, Treatment Type, Drug Type, Route of Administration, End-Users)
- Brazil
- Rest of Latin America
Middle East & Africa (Type, Treatment Type, Drug Type, Route of Administration, End-Users)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Imugene Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Otsuka Pharmaceuticals Co., Ltd (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb Company (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lilly (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (U.K.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Ipsen Pharma (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biosplice Therapeutics, Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Arbutus Biopharma (Canada)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
ASLAN Pharmaceuticals (Singapore)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments